Cercador de Publicacions

La producció científica dels nostres investigadors i investigadores és molt elevada. L'any 2022 es van publicar 1.629 articles a revistes científiques amb un factor d'impacte global que va superar els 15.000 punts.

Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain).

PMID: 31340964
Revista: BMJ Open
Any: 2019
Referència: BMJ Open. 2019 Jul 23;9(7):e028114. doi: 10.1136/bmjopen-2018-028114.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Agusti, M; Ariza, A; Badosa, E; Baneras, J; Baquerizo, B; Bardaji, A; Barta, L; Basaganyas, J; Bonet-Pineda, G; Cardenas, Merida et al.
DOI: 10.1136/bmjopen-2018-028114

Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors.

PMID: 31053787
Revista: EUROPEAN JOURNAL OF HUMAN GENETICS
Any: 2019
Referència: Eur J Hum Genet. 2019 Dec;27(12):1774-1782. doi: 10.1038/s41431-019-0415-4. Epub 2019 May 3.
Factor d'impacte: 3.65
Tipus de publicació: Revisió en revista internacional
Autors: Serra-Juhe, Clara, Tizzano, Eduardo F et al.
DOI: 10.1038/s41431-019-0415-4

Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors.

PMID: 31053787
Revista: EUROPEAN JOURNAL OF HUMAN GENETICS
Any: 2019
Referència: Eur J Hum Genet. 2019 Dec;27(12):1774-1782. doi: 10.1038/s41431-019-0415-4. Epub 2019 May 3.
Factor d'impacte:
Tipus de publicació: Revisió en revista internacional
Autors: Serra-Juhe, Clara; Tizzano, Eduardo F et al.
DOI: 10.1038/s41431-019-0415-4

Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology.

PMID: 31283872
Revista: Transplant Infectious Disease
Any: 2019
Referència: Transpl Infect Dis. 2019 Oct;21(5):e13141. doi: 10.1111/tid.13141. Epub 2019 Jul 22.
Factor d'impacte: 2.112
Tipus de publicació: Article en revista internacional
Autors: Luong, Me-Linh, Seidel, Danila, Grossi, Paolo, Husain, Shahid, Picard, Clement, Lass-Florl, Cornelia, Manuel, Oriol, Le Pavec, Jerome, Lortholary, Olivier, Nagel, Claudia et al.
DOI: 10.1111/tid.13141

Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology.

PMID: 31283872
Revista: Transplant Infectious Disease
Any: 2019
Referència: Transpl Infect Dis. 2019 Oct;21(5):e13141. doi: 10.1111/tid.13141. Epub 2019 Jul 22.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Aslam, Saima; Baddley, John; Benden, Christian; Bervar, Jean-Francois; Bhorade, Sangeeta; Blanchard, Elodie; Boussaud, Veronique; Brill, Anne Kathrin; Brugiere, Olivier; Budem, Marie et al.
DOI: 10.1111/tid.13141

Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.

PMID: 31333640
Revista: Frontiers in Immunology
Any: 2019
Referència: Front Immunol. 2019 Jul 3;10:1344. doi: 10.3389/fimmu.2019.01344. eCollection 2019.
Factor d'impacte: 4.716
Tipus de publicació: Revisió en revista internacional
Autors: Esposito, Susanna, Stefanelli, Paola, Fry, Norman K, Fedele, Giorgio, He, Qiushui, Paterson, Pauline, Tan, Tina, Knuf, Markus, Rodrigo, Carlos, Weil Olivier, Catherine et al.
DOI: 10.3389/fimmu.2019.01344

Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.

PMID: 31333640
Revista: Frontiers in Immunology
Any: 2019
Referència: Front Immunol. 2019 Jul 3;10:1344. doi: 10.3389/fimmu.2019.01344. eCollection 2019.
Factor d'impacte:
Tipus de publicació: Revisió en revista internacional
Autors: Edwards, Kathryn; Esposito, Susanna; Fedele, Giorgio; Flanagan, Katie L; Fry, Norman K; He, Qiushui; Hung, Ivan; Knuf, Markus; Lutsar, Iria; O'Ryan, Miguel et al.
DOI: 10.3389/fimmu.2019.01344

PET or MRI to improve response evaluation in clinical trials?

PMID: 31486372
Revista: LANCET ONCOLOGY
Any: 2019
Referència: Lancet Oncol. 2019 Aug;20(8):1060-1062. doi: 10.1016/S1470-2045(19)30465-6. Epub 2019 Jul 29.
Factor d'impacte: 35.386
Tipus de publicació: Editorial en revista internacional
Autors: Deroose, Christophe M, Gheysens, Olivier, Perez-Lopez, Raquel et al.
DOI: 10.1016/S1470-2045(19)30465-6

PET or MRI to improve response evaluation in clinical trials?

PMID: 31486372
Revista: LANCET ONCOLOGY
Any: 2019
Referència: Lancet Oncol. 2019 Aug;20(8):1060-1062. doi: 10.1016/S1470-2045(19)30465-6. Epub 2019 Jul 29.
Factor d'impacte:
Tipus de publicació: Editorial en revista internacional
Autors: Deroose, Christophe M; Gheysens, Olivier; Perez-Lopez, Raquel et al.
DOI: 10.1016/S1470-2045(19)30465-6

PET Scan: Nuclear Medicine Imaging in Myositis.

PMID: 31754890
Revista: Current Rheumatology Reports
Any: 2019
Referència: Curr Rheumatol Rep. 2019 Nov 21;21(11):64. doi: 10.1007/s11926-019-0864-3.
Factor d'impacte: 3.645
Tipus de publicació: Revisió en revista internacional
Autors: Selva-O'Callaghan, Albert, Gil-Vila, Albert, Simo-Perdigo, Marc, Trallero-Araguas, Ernesto, Alvarado-Cardenas, Marcelo, Pinal-Fernandez, Iago et al.
DOI: 10.1007/s11926-019-0864-3

PET Scan: Nuclear Medicine Imaging in Myositis.

PMID: 31754890
Revista: Current Rheumatology Reports
Any: 2019
Referència: Curr Rheumatol Rep. 2019 Nov 21;21(11):64. doi: 10.1007/s11926-019-0864-3.
Factor d'impacte:
Tipus de publicació: Revisió en revista internacional
Autors: Alvarado-Cardenas, Marcelo; Gil-Vila, Albert; Pinal-Fernandez, Iago; Selva-O'Callaghan, Albert; Simo-Perdigo, Marc; Trallero-Araguas, Ernesto et al.
DOI: 10.1007/s11926-019-0864-3

Phaeohyphomycosis caused by Medicopsis romeroi in solid organ transplant recipients: report of two cases and comprehensive review of the literature.

PMID: 30865352
Revista: Transplant Infectious Disease
Any: 2019
Referència: Transpl Infect Dis. 2019 Jun;21(3):e13072. doi: 10.1111/tid.13072. Epub 2019 Mar 27.
Factor d'impacte: 2.112
Tipus de publicació: Revisió en revista internacional
Autors: Los-Arcos, Ibai, Royuela, Meritxell, Martin-Gomez, Maria Teresa, Alastruey-Izquierdo, Ana, Sellares, Joana, Perello, Manel, Castells, Lluis, Dopazo, Cristina, Gavalda, Joan, Len, Oscar et al.
DOI: 10.1111/tid.13072

Phaeohyphomycosis caused by Medicopsis romeroi in solid organ transplant recipients: report of two cases and comprehensive review of the literature.

PMID: 30865352
Revista: Transplant Infectious Disease
Any: 2019
Referència: Transpl Infect Dis. 2019 Jun;21(3):e13072. doi: 10.1111/tid.13072. Epub 2019 Mar 27.
Factor d'impacte:
Tipus de publicació: Revisió en revista internacional
Autors: Alastruey-Izquierdo, Ana; Castells, Lluis; Dopazo, Cristina; Gavalda, Joan; Len, Oscar; Los-Arcos, Ibai; Martin-Gomez, Maria Teresa; Perello, Manel; Royuela, Meritxell; Sellares, Joana et al.
DOI: 10.1111/tid.13072

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

PMID: 31183514
Revista: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Any: 2019
Referència: Cancer Chemother Pharmacol. 2019 Sep;84(3):539-550. doi: 10.1007/s00280-019-03871-w. Epub 2019 Jun 10.
Factor d'impacte: 3.008
Tipus de publicació: Article en revista internacional
Autors: Wang, Bei, Kirschbrown, Whitney P, Hoff, Paulo M, Shah, Manish A, Shen, Lin, Kang, Yoon-Koo, Alsina, Maria, Girish, Sandhya, Garg, Amit, Ohtsu, Atsushi et al.
DOI: 10.1007/s00280-019-03871-w

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

PMID: 31183514
Revista: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Any: 2019
Referència: Cancer Chemother Pharmacol. 2019 Sep;84(3):539-550. doi: 10.1007/s00280-019-03871-w. Epub 2019 Jun 10.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Alsina, Maria; Garg, Amit; Girish, Sandhya; Hoff, Paulo M; Kang, Yoon-Koo; Kirschbrown, Whitney P; Nijem, Ihsan; Ohtsu, Atsushi; Shah, Manish A; Shen, Lin et al.
DOI: 10.1007/s00280-019-03871-w

Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes.

PMID: 30633087
Revista: THERAPEUTIC DRUG MONITORING
Any: 2019
Referència: Ther Drug Monit. 2019 Jun;41(3):376-382. doi: 10.1097/FTD.0000000000000595.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Fortun, Jesus; Grau, Santiago; Liano, Fernando; Luque, Sonia; Roberts, Jason A; Tenorio-Canamas, Teresa et al.
DOI: 10.1097/FTD.0000000000000595

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

PMID: 29954928
Revista: HAEMATOLOGICA
Any: 2019
Referència: Haematologica. 2019 Apr;104(4):778-788. doi: 10.3324/haematol.2017.180505. Epub 2018 Jun 28.
Factor d'impacte: 7.57
Tipus de publicació: Article en revista internacional
Autors: Guerrero-Hernandez, Martina, Rodriguez, Vanina, Soldini, Davide, Valera, Alexandra, Moros, Alexandra, Climent, Fina, Gonzalez-Barca, Eva, Mercadal, Santiago, Arenillas, Leonor, Calvo, Xavier et al.
DOI: 10.3324/haematol.2017.180505

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

PMID: 29954928
Revista: HAEMATOLOGICA
Any: 2019
Referència: Haematologica. 2019 Apr;104(4):778-788. doi: 10.3324/haematol.2017.180505. Epub 2018 Jun 28.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Arenillas, Leonor; Borrell, Jose Ignacio; Bueno, Clara; Calvo, Xavier; Campo, Elias; Cardesa-Salzmann, Teresa; Casanova, Isolda; Climent, Fina; Clot, Guillem; Colomer, Dolors et al.
DOI: 10.3324/haematol.2017.180505

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.

PMID: 31581671
Revista: Cancers
Any: 2019
Referència: Cancers (Basel). 2019 Oct 2;11(10). pii: cancers11101483. doi: 10.3390/cancers11101483.
Factor d'impacte: 6.162
Tipus de publicació: Revisió en revista internacional
Autors: Reyes-Garau, Diana, Ribeiro, Marcelo L, Roue, Gael et al.
DOI: 10.3390/cancers11101483

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.

PMID: 31581671
Revista: Cancers
Any: 2019
Referència: Cancers (Basel). 2019 Oct 2;11(10). pii: cancers11101483. doi: 10.3390/cancers11101483.
Factor d'impacte:
Tipus de publicació: Revisió en revista internacional
Autors: Reyes-Garau, Diana; Ribeiro, Marcelo L; Roue, Gael et al.
DOI: 10.3390/cancers11101483

Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

PMID: 31481511
Revista: CLINICAL CANCER RESEARCH
Any: 2019
Referència: Clin Cancer Res. 2019 Dec 1;25(23):6976-6985. doi: 10.1158/1078-0432.CCR-19-1338. Epub 2019 Sep 3.
Factor d'impacte: 8.911
Tipus de publicació: Article en revista internacional
Autors: Cleverly, Ann, Lahn, Michael M, Janssen, Jan, Zhao, Yumin, Chiang, Alan, Giagounidis, Aristoteles, Guba, Susan C, Sridharan, Ashwin, Gueorguieva, Ivelina, Girvan, Alicia et al.
DOI: 10.1158/1078-0432.CCR-19-1338

Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

PMID: 31481511
Revista: CLINICAL CANCER RESEARCH
Any: 2019
Referència: Clin Cancer Res. 2019 Dec 1;25(23):6976-6985. doi: 10.1158/1078-0432.CCR-19-1338. Epub 2019 Sep 3.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Bhagat, Tushar D; Chiang, Alan; Cleverly, Ann; da Silva Ferreira, Mariana; Giagounidis, Aristoteles; Girvan, Alicia; Guba, Susan C; Gueorguieva, Ivelina; Janssen, Jan; Komrokji, Rami S et al.
DOI: 10.1158/1078-0432.CCR-19-1338

Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.

PMID: 32085233
Revista: ANNALS OF ONCOLOGY
Any: 2019
Referència: Ann Oncol. 2019 Jul;30 Suppl 4:iv62. doi: 10.1093/annonc/mdz155.224. Epub 2019 Dec 4.
Factor d'impacte: 14.196
Tipus de publicació: Carta o abstract
Autors: Macarulla, T, Javle, M, Borbath, I, Clarke, S, Hitre, E, Louvet, C, Valle, J, Weiss, K, Berman, C, Howland, M et al.
DOI: 10.1093/annonc/mdz155.224

Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.

PMID: 32085233
Revista: ANNALS OF ONCOLOGY
Any: 2019
Referència: Ann Oncol. 2019 Jul;30 Suppl 4:iv62. doi: 10.1093/annonc/mdz155.224. Epub 2019 Dec 4.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Abou-Alfa, G; Berman, C; Borbath, I; Cho, T; Clarke, S; Hitre, E; Howland, M; Javle, M; Louvet, C; Macarulla, T et al.
DOI: 10.1093/annonc/mdz155.224

Publicacions

Cercador de Publicacions

Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain).

Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors.

Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors.

Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology.

Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology.

Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.

Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.

PET or MRI to improve response evaluation in clinical trials?

PET or MRI to improve response evaluation in clinical trials?

PET Scan: Nuclear Medicine Imaging in Myositis.

PET Scan: Nuclear Medicine Imaging in Myositis.

Phaeohyphomycosis caused by Medicopsis romeroi in solid organ transplant recipients: report of two cases and comprehensive review of the literature.

Phaeohyphomycosis caused by Medicopsis romeroi in solid organ transplant recipients: report of two cases and comprehensive review of the literature.

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes.

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.

Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.

Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.

Patronat:

Col·labora:

Acreditacions: